GetTopicDetailResponse(id=374ce12041, topicName=Evinacumab, introduction=Evinacumab, content=null, image=null, comments=1, allHits=1843, url=https://h5.medsci.cn/topic?id=7120, type=1, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=93389, tagList=[TagDto(tagId=93389, tagName=Evinacumab)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2249191, encodeId=9fdf224919139, content=<a href='/topic/show?id=d4d196630b4' target=_blank style='color:#2F92EE;'>#銀屑病#</a> <a href='/topic/show?id=374ce12041' target=_blank style='color:#2F92EE;'>#Evinacumab#</a>, objectTitle=Asia Pac J Clin Nutr：中國學(xué)者基于孟德爾隨機化的證據(jù)，揭示Evinacumab通過抑制ANGPTL3降低銀屑病風(fēng)險, objectType=article, longId=860576, objectId=56858605e6d8, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221229/1672303193754_2570354.jpg, objectUrl=/article/show_article.do?id=56858605e6d8, replyNumber=0, likeNumber=61, createdTime=2025-01-22, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陜西省, moduleDTOList=[ModuleDTO(moduleId=56858605e6d8, moduleTitle=Asia Pac J Clin Nutr：中國學(xué)者基于孟德爾隨機化的證據(jù)，揭示Evinacumab通過抑制ANGPTL3降低銀屑病風(fēng)險, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=56858605e6d8)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2209540, encodeId=b67b2209540ea, content=<a href='/topic/show?id=374ce12041' target=_blank style='color:#2F92EE;'>#Evinacumab#</a> <a href='/topic/show?id=1fa7115438fd' target=_blank style='color:#2F92EE;'>#純合子家族性高膽固醇血癥#</a>, objectTitle=Eur Heart J：Evinacumab治療純合子家族性高膽固醇血癥的長期安全性和有效性, objectType=article, longId=829735, objectId=b1a2829e35fc, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240612/1718184552306_92910.jpg, objectUrl=/article/show_article.do?id=b1a2829e35fc, replyNumber=0, likeNumber=100, createdTime=2024-06-12, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=b1a2829e35fc, moduleTitle=Eur Heart J：Evinacumab治療純合子家族性高膽固醇血癥的長期安全性和有效性, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=b1a2829e35fc)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1247616, encodeId=4a78124e616d2, content=<a href='/topic/show?id=aa8d252611' target=_blank style='color:#2F92EE;'>#ANGPTL3#</a>單抗<a href='/topic/show?id=374ce12041' target=_blank style='color:#2F92EE;'>#Evinacumab#</a>治療<a href='/topic/show?id=23814643930' target=_blank style='color:#2F92EE;'>#家族性高膽固醇血癥#</a>的III期臨床成功，未來有望成為常規(guī)<a href='/topic/show?id=3323981903c' target=_blank style='color:#2F92EE;'>#降脂#</a>的藥物, objectTitle=Regeneron的ANGPTL3單抗evinacumab治療家族性高膽固醇血癥的III期臨床成功, objectType=article, longId=177716, objectId=cb201e7716eb, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/webeditor/uploadfile/201908/20190815110335613.jpg, objectUrl=/article/show_article.do?id=cb201e7716eb, replyNumber=0, likeNumber=168, createdTime=2022-09-07, rootId=0, userName=小小醫(yī)者, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb201e7716eb, moduleTitle=Regeneron的ANGPTL3單抗evinacumab治療家族性高膽固醇血癥的III期臨床成功, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=cb201e7716eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
